All news (page 4)

• 

  7 April 2026

  Technip Energies authorized to advance Commonwealth LNG pre‑FID

  Substantial authorization continues EPC work on a 9.5 Mtpa LNG export project in Louisiana, supporting delivery of six modular SnapLNG trains ahead of final investment decision
• 

  7 April 2026

  Axens to License Technologies for America First Refinery in Brownsville, TX

  First new US refinery in 50+ years will process over 60 million bbl/yr of domestic shale oil into gasoline, diesel and jet fuel using proven low‑energy refining technologies
• 

  7 April 2026

  ASPİLSAN Enerji signs $5.2M LFP cell line deal with Top Material and $600K electrode export pact

  Turnkey installation and tech transfer to build domestic battery cell production; commissioning in 2027. New cells for defense and critical systems, raising localization and exports.
• 

  7 April 2026

  Nextchem (MAIRE) opens Beijing office to expand sustainable technology presence in China and Asia

  Office signals strategic push into Chinese market, deepening local partnerships, leveraging an established presence since 1994 and focusing on tech innovation for energy and critical raw materials.
• 

  7 April 2026

  Eni finds 2 Tcf gas and 130 Mbbl condensate offshore Egypt

  Denise W in Temsah Concession: 70 km offshore, 95 m water depth, ~50 m net-pay high-quality sandstone close to infrastructure for fast-track tie‑in; concession renewed; Petrobel operator, bp 50%.
• 

  7 April 2026

  Elkem launches eco‑designed silicones for high‑performance sustainable beauty

  Adds two eco‑designed elastomers in a sunflower‑derived alkane for improved sensory and SPF performance, plus an emulsifying elastomer that enhances pigment/UV dispersion, stability and glide.

• 

  6 April 2026

  Amgen reports positive Phase 3 topline results for subcutaneous TEPEZZA in moderate-to-severe thyroid eye disease

  Phase 3 subcutaneous TEPEZZA met primary endpoint in moderate-to-severe TED: 76.7% proptosis response vs 19.6% placebo; mean −3.17 mm reduction; safety consistent; mild injection-site AEs
• 

  6 April 2026

  Fluor awarded FEL-2 contract by X‑energy for Seadrift SMR project

  FEL-2 will define and plan four 80 MW SMRs at Seadrift to supply power and steam. DOE-backed; construction permit under NRC review; intended as first industrial advanced reactor in N.A.
• 

  6 April 2026

  Velocys and Varhad Capital MOU to develop Make‑In‑India biomass‑to‑SAF

  MOU to develop Make‑In‑India biomass-to-SAF projects using operational gasification and Fischer–Tropsch tech; hub‑and‑spoke model for distributed, cost‑competitive, low‑carbon SAF
• 

  6 April 2026

  Petrobras names Angélica Laureano to executive board

  Claudio Schlosser's mandate ended immediately as Exec. Dir., Logistics & Markets. Angelica Laureano takes over 7 Apr 2026-Apr 2027. William Franca temporarily covers Energy Transition/Sustainability.
• 

  6 April 2026

  Mesabi Metallics raises $150M from Macquarie

  World-scale DR-grade iron ore mine and pellet plant in Nashwauk, MN, set for Q3 2026 start; $2.5B project on 16,000+ acres, EXIM support, $2B+ equity invested and 800 workers onsite.
• 

  6 April 2026

  Chugai: Study in Blood Identifies Complement-Activated ITP Subgroup

  Joint Osaka Univ study published in Blood finds three ITP platelet‑destruction mechanisms and suggests a simple clinical test to identify patients who may benefit from complement inhibitors.
• 

  6 April 2026

  James Robinson Speciality Ingredients and Mitsui Fine Chemicals partner to distribute Jarocol® hair dyes in Japan

  Exclusive distribution of a hair-dye range; offers formulators colours from grey coverage to vibrant fashion shades, with technical support and local market expertise.
• 

  6 April 2026

  Trinseo: The Node That Ran Out of Time

  Lender waivers expiring; missed interest; market cap far below debt. Costly M&A and validated PC/ABS dissolution recycling tech, but cash‑strapped amid energy shocks and no sovereign backer—sale likely.
• 

  3 April 2026

  Tengizchevroil (TCO) at GECA Forum: Central Asia Hydrocarbon Development

  GECA Forum in Astana brought gov, industry and experts together to discuss Central Asia hydrocarbon development: exploration, tech, energy security, sustainability, safety and regional benefits.
• 

  3 April 2026

  Borealis Kallo PDH2 2025 update

  Project surpassed 97% construction and precommissioning in 2025; remaining insulation and commissioning work. Start-up planned for H2 2026.
• 

  2 April 2026

  Airgas (Air Liquide) supplies high-pressure nitrogen for NASA Artemis II

  Provided high-pressure nitrogen from Merritt Island to support a crewed lunar flight, meeting peak flow requirements for the launch vehicle during final countdown and liftoff.
• 

  2 April 2026

  FDA approves Lilly's Foundayo (orforglipron), oral GLP‑1 for anytime dosing

  Oral GLP‑1 produced ~12% mean weight loss (~27 lb) at 72 weeks in Phase 3. Available via direct home delivery with low‑cost copays; carries thyroid tumor and GI side‑effect warnings.
• 

  2 April 2026

  SPIE to acquire Czech cleanroom specialist BLOCK group

  Acquisition adds turnkey cleanroom design, engineering and automation for pharma, biotech and microelectronics. Target posted €50M (FY2025) and ~160 staff. Closing expected Q2 2026.
• 

  2 April 2026

  bp names Carol Howle deputy CEO

  Deputy CEO continues to lead supply, trading & shipping; will oversee portfolio review and long‑term strategy beyond 2027. Strategy & sustainability now report to her. She has 25 years' tenure.
• 

  2 April 2026

  Trinseo raises European PS and ABS prices €590/t; SAN €600/t

  Price increases take effect Apr 1, 2026, or as governed by existing contract terms.
• 

  2 April 2026

  Petrobras settles Shared Tupi Field redetermination payments

  On 31/03/2026 received ~R$3bn from partners and paid ~R$600m to the Union; participation increased from 67.216% to 67.457% effective 01/12/2025; amounts recognized in 4Q25.
• 

  2 April 2026

  Novo Nordisk: Wegovy pill shows greater weight loss and lower discontinuation vs orforglipron in indirect comparison

  Indirect comparison (ORION) found oral semaglutide 25 mg led to ~3% greater weight loss vs orforglipron; orforglipron had higher discontinuation for AEs (esp. GI); 84% preferred semaglutide-like profile.
• 

  2 April 2026

  Bilfinger completes acquisition of Teknokon businesses in Türkiye

  Deal closed April 1, 2026: adds ~1,000 specialists, upper double‑digit million‑€ revenue; positions as regional hub linking Eastern Europe and Middle East; full integration within a year.
• 

  2 April 2026

  TotalEnergies and Masdar form $2.2bn JV for onshore renewables in Asia

  Merger of onshore solar, wind and storage in nine Asian countries, combining 3 GW operational and 6 GW advanced-development (to 2030). HQ in ADGM; ~200 staff; closing subject to approvals.
• 

  2 April 2026

  Indaver and EcoWerf shift PMD transport to waterways

  PMD collection now shipped by inland vessel: 10,000 t/year (replacing ~2,320 road trips), press reduces volume by two-thirds, cuts CO2 by ~127 t/yr; plan to move half waste to waterways.
• 

  2 April 2026

  Sasol's Sasolburg Operations Retains Green Drop Certification

  Plant scored 96.8% (92.9% WSI), ranked 2nd; won Best Private Technical Site TSA (94%); top scores in capacity and effluent compliance; treats 27.01 kL/d and supports local sanitation projects.
• 

  2 April 2026

  Perpetual Next selects Bilfinger for Methanol Moerdijk permitting

  Covers EIA, environmental and nature permitting, stakeholder coordination and QA in sprint-based delivery for a large biomethanol plant - ~216,000 t/yr output.
• 

  2 April 2026

  EU approves Merck's KEYTRUDA with paclitaxel ± bevacizumab for PD‑L1 (CPS≥1) platinum‑resistant recurrent ovarian cancer after 1–2 prior regimens

  Phase 3 KEYNOTE‑B96 showed significant progression‑free and overall survival gains versus placebo+paclitaxel (±bevacizumab), supporting EU approval as the first PD‑1 inhibitor option.
• 

  2 April 2026

  Merck starts pivotal Phase 2b/3 trial of MK-8748 (Tiespectus) for neovascular AMD

  Pivotal Phase 2b/3 MALBEC trial begins for a bispecific Tie2 agonist/VEGF inhibitor in neovascular AMD; randomized vs aflibercept, primary endpoint mean BCVA change at Year 1.